
For years technology has been advancing and coming closer and closer to a “closed loop” artificial pancreas state. The benefits of such technologies has been recognized and supported by patients, insurance companies and thought leaders in the industry. With that said the most basic and inexpensive form of insulin delivery has been without technological advancements.


